Accéder au contenu
Merck

Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease.

Immunity (2019-12-31)
Sebastian Werneburg, Jonathan Jung, Rejani B Kunjamma, Seung-Kwon Ha, Nicholas J Luciano, Cory M Willis, Guangping Gao, Natalia P Biscola, Leif A Havton, Stephen J Crocker, Brian Popko, Daniel S Reich, Dorothy P Schafer
RÉSUMÉ

Multiple sclerosis (MS) is a demyelinating, autoimmune disease of the central nervous system. While work has focused on myelin and axon loss in MS, less is known about mechanisms underlying synaptic changes. Using postmortem human MS tissue, a preclinical nonhuman primate model of MS, and two rodent models of demyelinating disease, we investigated synapse changes in the visual system. Similar to other neurodegenerative diseases, microglial synaptic engulfment and profound synapse loss were observed. In mice, synapse loss occurred independently of local demyelination and neuronal degeneration but coincided with gliosis and increased complement component C3, but not C1q, at synapses. Viral overexpression of the complement inhibitor Crry at C3-bound synapses decreased microglial engulfment of synapses and protected visual function. These results indicate that microglia eliminate synapses through the alternative complement cascade in demyelinating disease and identify a strategy to prevent synapse loss that may be broadly applicable to other neurodegenerative diseases. VIDEO ABSTRACT.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide rétinoïque, ≥98% (HPLC), powder
Sigma-Aldrich
Adjuvant complet de Freund, cell suspension
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Anticorps monoclonal anti-protéine acide fibrillaire gliale (GFAP) antibody produced in mouse, clone G-A-5, ascites fluid
Sigma-Aldrich
Anti-Neurofilament 200 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anticorps anti-transporteur vésiculaire du glutamate de type 1, serum, Chemicon®
Sigma-Aldrich
Anticorps anti-APP A4, a. a. 66 à 81 de l′APP {NT}, clone 22C11, clone 22C11, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-NeuN, from chicken, purified by affinity chromatography
Sigma-Aldrich
Anticorps anti-protéine basique de la myéline, acides aminés 82 à 87, culture supernatant, clone 12, Chemicon®
Sigma-Aldrich
Anticorps anti-PSD95 (protéine de densité post-synaptique 95), clone 6G6-1C9, clone 6G6-1C9, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-MOG (glycoprotéine de myéline des oligodendrocytes), clone 8-18C5, Chemicon®, from mouse
Supelco
4-Hydroxytamoxifène, analytical standard, (E) and (Z) isomers (50:50)
Sigma-Aldrich
Anticorps anti-glycoprotéine associée à la myéline, clone 513, clone 513, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-Aldh1L1, clone N103/39, clone N103/39, from mouse
Sigma-Aldrich
Anticorps anti-protéine fluorescente verte, Chemicon®, from rabbit
Supelco
6α-Naloxol solution, 1.0 mg/mL in methanol, certified reference material, Cerilliant®